| | | 重庆正川医药包装材料股份有限公司 第四届董事会第九次会议决议公告 重庆正川医药包装材料股份有限公司（以下简称"公司"）于 2023 年 8 月 11 日以电子邮件或电话等形式向各位董事发出了召开第四届董事会第九次会议 的通知。会议于 2023 年 8 月 18 日以现场结合通讯方式在正川永成研发楼三楼会 议室召开，应参加董事 9 名，实际参加董事 9 名。 本次会议由董事长邓勇先生召集和主持。会议的召集、召开和表决程序均符 合《公司法》等法律、行政法规以及《公司章程》《公司董事会议事规则》的有 关规定，会议的召集、召开合法有效。 二、董事会会议审议情况 1、会议审议通过了《关于不向下修正"正川转债"转股价格的议案》 公司本次不向下修正"正川转债"转股价格，同时在未来六个月内（即 2023 年 8 月 19 日至 2024 年 2 月 18 日），如再次触发"正川转债"转股价格向下修正 条款，亦不提出向下修正方案。自 2024 年 2 月 19 日起首个交易日重新开始计算， 若再次触发"正川转债"转股价格向下修正条款，届时董事会将再次召开会议决 定是否行使"正川转债"的转股价格向下修正权利。 本公司 ...

| 证券代码：603976 | 证券简称：正川股份 | 公告编号：2023-050 | | --- | --- | --- | | 债券代码：113624 | 债券简称：正川转债 | | 重要内容提示： 自2023年7月31日至2023年8月18日，重庆正川医药包装材料股份有限公司 （以下简称"公司"）股票已出现连续三十个交易日中至少有十五个交易日的收 盘价低于当期转股价格的90%之情形，触发"正川转债"转股价格向下修正条款。 经公司第四届董事会第九次会议审议，公司董事会决定本次不向下修正"正 川转债"转股价格，同时在未来六个月内（即2023年8月19日至2024年2月18日）， 如再次触发"正川转债"转股价格向下修正条款，亦不提出向下修正方案。自 2024年2月19日起首个交易日重新开始计算，若再次触发"正川转债"转股价格 向下修正条款，届时董事会将再次召开会议决定是否行使"正川转债"的转股价 格向下修正权利。 一、可转债基本情况 经中国证券监督管理委员会证监许可[2021]198 号《关于核准重庆正川医药 包装材料股份有限公司公开发行可转换公司债券的批复》核准，公司于 2021 年 4 月 28 日公开发 ...

| | | 重庆正川医药包装材料股份有限公司 关于使用闲置自有资金进行现金管理的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 在不影响公司日常经营活动，确保资金安全性、流动性的前提下，对公司闲 置自有资金进行现金管理，进一步提高资金使用效率，增加公司和股东收益。 重要内容提示： 现金管理产品提供方：渝农商理财有限责任公司（以下简称"渝农商理 财"）； 现金管理产品名称：渝农商理财益尊封闭式2023年第32008期； 现金管理金额：共计5,000万元； 现金管理期限：99天； 履行的审议程序：公司于2023年6月30日召开了第四届董事会第七次会议、 第四届监事会第五次会议，审议通过了《关于使用闲置自有资金进行现金管理的 议案》，同意公司使用额度不超过人民币25,000万元的闲置自有资金进行现金管 理，以上资金额度在董事会审议通过之日起12个月内可以循环滚动使用。 一、本次现金管理概况 （一）目的 （二）资金来源 本次现金管理的资金全部来源于闲置自有资金。 （三）现金管理产品的基本情况 | 产品提 | 产品类型 | 产 ...

| 证券代码：603976 | 证券简称：正川股份 | 公告编号：2023-047 | | --- | --- | --- | | 债券代码：113624 | 债券简称：正川转债 | | 重庆正川医药包装材料股份有限公司 关于"正川转债"预计满足转股价格修正条件的 提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、可转债发行上市概况 经中国证券监督管理委员会证监许可[2021]198号《关于核准重庆正川医药 包装材料股份有限公司公开发行可转换公司债券的批复》核准，重庆正川医药包 装材料股份有限公司（以下简称"公司"）于2021年4月28日公开发行可转换公司 债券405万张，每张面值人民币100元，本次发行可转换公司债券募集资金总额为 人民币405,000,000元，期限6年（即自2021年4月28日至2027年4月27日），债券 票面年利率为：第一年0.50%、第二年0.70%、第三年1.20%、第四年1.80%、第五 年2.40%、第六年3.00%。 根据《上海证券交易所股票上市规则》和《重庆正川医药包装 ...

重要内容提示： 投资者可于 2023 年 05 月 10 日(星期三) 至 05 月 16 日(星期二)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 zczq@cqzcjt.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回 答。 重庆正川医药包装材料股份有限公司（以下简称"公司"）已于 2023 年 4 月 27 日发布公司 2022 年度报告，为便于广大投资者更全面深入地了解公司 2022 年度经营成果、财务状况，公司计划于 2023 年 05 月 17 日 上午 10:00-11:30 举行业绩说明会，就投资者关心的问题进行交流。 一、 说明会类型 | 证券代码：603976 | 证券简称：正川股份 | 公告编号：2023-027 | | --- | --- | --- | | 债券代码：113624 | 债券简称：正川转债 | | 重庆正川医药包装材料股份有限公司 关于召开 2022 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 董事会秘书：刘茜 ...

Financial Performance - The company's operating revenue for Q1 2023 was CNY 225,554,847.36, representing a year-on-year increase of 0.41%[3] - The net profit attributable to shareholders decreased by 49.85% to CNY 12,994,745.54 compared to the same period last year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses also fell by 49.72% to CNY 10,786,507.71[3] - The basic and diluted earnings per share were both CNY 0.09, down by 47.06% year-on-year[3] - Total revenue for Q1 2023 was CNY 225,554,847.36, a slight increase of 0.41% compared to CNY 224,626,184.94 in Q1 2022[14] - Net profit for Q1 2023 was CNY 12,994,745.54, a decrease of 49.8% from CNY 25,910,867.89 in Q1 2022[15] - The total comprehensive income for the first quarter of 2023 was CNY 12,994,745.54, compared to CNY 25,910,867.89 in the same period of 2022, indicating a decrease of approximately 49.8%[16] - Basic earnings per share for Q1 2023 were CNY 0.09, down from CNY 0.17 in Q1 2022, reflecting a decline of 47.1%[16] Cash Flow and Liquidity - The net cash flow from operating activities increased significantly by 173.13% to CNY 39,221,086.61, mainly due to the maturity of bank acceptance bills[3][6] - Net cash flow from operating activities for Q1 2023 was CNY 39,221,086.61, a significant improvement from a net outflow of CNY 53,634,995.93 in Q1 2022[19] - Cash inflow from operating activities totaled CNY 237,657,119.10 in Q1 2023, compared to CNY 164,902,876.84 in Q1 2022, representing an increase of approximately 43.9%[19] - Cash outflow from operating activities decreased to CNY 198,436,032.49 in Q1 2023 from CNY 218,537,872.77 in Q1 2022, a reduction of about 9.2%[19] - The ending balance of cash and cash equivalents as of the end of Q1 2023 was CNY 141,004,035.98, down from CNY 313,825,947.96 at the end of Q1 2022, a decrease of approximately 55.1%[20] - The company experienced a net decrease in cash and cash equivalents of CNY 42,430,805.71 in Q1 2023, compared to a decrease of CNY 33,960,475.67 in Q1 2022, indicating ongoing liquidity challenges[20] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,011,134,906.46, a slight increase of 0.17% from the end of the previous year[4] - The company's total assets as of March 31, 2023, were CNY 2,011,134,906.46, compared to CNY 2,007,660,704.19 at the end of 2022[13] - Current assets totaled CNY 998,774,958.70, slightly up from CNY 991,745,118.14 at the end of 2022[12] - Total liabilities decreased to CNY 813,941,668.09 from CNY 823,465,211.36 at the end of 2022[13] - Cash and cash equivalents were CNY 182,611,697.04, down from CNY 212,432,533.40 at the end of 2022[12] - Accounts receivable increased to CNY 185,523,812.16 from CNY 141,283,714.62 at the end of 2022[12] - Inventory decreased to CNY 200,654,515.22 from CNY 209,426,565.25 at the end of 2022[12] Shareholder Information - The company reported a total of 23,842 common shareholders at the end of the reporting period[8] - The largest shareholder, Chongqing Zhengchuan Investment Management Co., Ltd., holds 39.07% of the shares[9] Government Support - The company received government subsidies amounting to CNY 931,555.48, which are closely related to its normal business operations[5] Research and Development - The company reported a decrease in research and development expenses to CNY 4,126,878.25 from CNY 4,888,245.32 in Q1 2022[15] Investment Activities - The net cash flow from investing activities was negative CNY 81,111,616.31 in Q1 2023, compared to a positive CNY 19,920,770.27 in Q1 2022, indicating a significant shift in investment strategy[19] - The company reported cash received from the recovery of investments amounting to CNY 110,000,000.00 in Q1 2023, an increase from CNY 100,000,000.00 in Q1 2022[19] Accounting Standards - The company plans to implement new accounting standards starting January 1, 2023, which may impact financial reporting and performance metrics going forward[20]

Financial Performance - In 2022, the company's operating revenue was CNY 796,198,292.56, a slight decrease of 0.06% compared to CNY 796,657,258.00 in 2021[23] - The net profit attributable to shareholders of the listed company for 2022 was CNY 64,765,035.84, down 39.25% from CNY 106,603,635.45 in 2021[23] - The net cash flow from operating activities decreased by 63.39% to CNY 38,426,207.67 in 2022, compared to CNY 104,966,819.34 in 2021[23] - The basic earnings per share for 2022 were CNY 0.43, a decrease of 39.44% from CNY 0.71 in 2021[24] - The weighted average return on equity decreased to 5.51% in 2022, down 4.15 percentage points from 9.66% in 2021[24] - The net cash flow from operating activities was negative in the first quarter at -53,634,995.93 RMB, but turned positive in the second quarter at 65,304,832.03 RMB[26] - Non-recurring gains and losses amounted to 7,086,079.07 RMB in 2022, with government subsidies contributing 5,057,327.65 RMB[28] - The company reported a net cash flow from operating activities of 38.43 million RMB, a decrease of 63.39% from the previous year[42] - Financial expenses increased by 259.34% to 14.82 million RMB, primarily due to increased bond interest expenses[42] Assets and Liabilities - The total assets of the company at the end of 2022 were CNY 2,007,660,704.19, an increase of 2.41% from CNY 1,960,497,669.74 at the end of 2021[23] - The net assets attributable to shareholders of the listed company increased by 1.56% to CNY 1,184,195,492.83 at the end of 2022[23] - The company's debt-to-asset ratio increased slightly to 41.02% from 40.53% in the previous year[162] - Total liabilities increased to $823,465,211.36 from $794,529,117.74, marking an increase of around 3.6%[200] - Current liabilities rose to $389,663,830.12 compared to $378,182,939.67, an increase of about 2.9%[200] - Non-current liabilities totaled $433,801,381.24, up from $416,346,178.07, reflecting a growth of approximately 4.0%[200] Production and Market Development - The company made significant progress in the market layout of borosilicate products, adding over 100 potential new customers[34] - Sales performance remained stable, with oral liquid products achieving record sales and injection products showing a year-on-year growth trend[34] - The first borosilicate furnace underwent technical upgrades, leading to improved quality and production capacity[34] - The company initiated the second borosilicate furnace, further consolidating its technology and enhancing competitive production capabilities[34] - Continuous upgrades and optimization of production equipment were implemented to improve efficiency and reduce costs[34] - The company is actively expanding its production capacity for borosilicate glass tubes and bottles to meet growing market demand[36] Research and Development - Research and development expenses increased by 58.22% to 19.11 million RMB, reflecting a stronger focus on innovation[42] - The total R&D investment for the period was 47,540,569.07 yuan, representing 5.97% of the operating income[58] - The company has 261 R&D personnel, making up 14.60% of the total workforce[59] - The company is committed to enhancing its research and development capabilities to continuously upgrade production processes and meet increasing regulatory standards[75] Strategic Partnerships and Customer Base - The company has formed deep strategic partnerships with over 600 domestic clients, including major pharmaceutical enterprises[39] - The company’s top five customers accounted for 30.05% of total annual sales, indicating a reliance on a limited customer base[54] - The total revenue from its top two customers was 9,925.86 million yuan, accounting for 12.51% of the annual total sales[55] Environmental and Sustainability Initiatives - The company invested CNY 1,364,000 in environmental protection during the reporting period[116] - The company has established a comprehensive environmental protection system and internal control framework to mitigate environmental risks[117] - The company reported no instances of exceeding pollutant discharge standards during the reporting period[118] - The company has implemented carbon reduction measures, including the adoption of all-oxygen combustion technology, which is expected to reduce energy consumption and carbon emissions[125] - The company achieved a suspended solid discharge concentration of 17.7 mg/L, significantly below the limit of 70 mg/L[119] Governance and Management - The company held 2 shareholder meetings during the reporting period, ensuring compliance with legal regulations and protecting the rights of minority investors[81] - The board of directors convened 8 meetings, adhering to relevant laws and regulations to ensure scientific decision-making and protect shareholder interests[81] - The supervisory board held 7 meetings, fully complying with legal requirements to oversee the company's lawful operations[81] - The company actively communicated with minority shareholders to keep them informed about significant developments and to gather feedback for the board of directors[82] - The company strictly followed information disclosure obligations, ensuring transparency and accuracy in reporting[82] Future Outlook and Risks - The company has outlined potential risks in its future development plans, which investors should be aware of[9] - The company faces potential risks from policy changes that may raise packaging material standards, requiring ongoing investment in technology and production upgrades[75] - The company is dependent on the pharmaceutical industry, and any downturn in this sector could directly impact its performance and demand for packaging materials[76] - The company recognizes the risk of product substitution as new materials may emerge in the pharmaceutical packaging industry, potentially affecting demand for its glass packaging products[76] Shareholder Information - Chairman Deng Yong held 29,305,364 shares at the beginning and end of the year, with a pre-tax remuneration of 862,500 CNY[86] - Director Jiang Hui, who left the position, increased her indirect shareholding from 0 to 2,145,790 shares, with a pre-tax remuneration of 223,400 CNY[86] - The total remuneration for all directors, supervisors, and senior management at the end of the reporting period amounted to 5.2946 million yuan[90] - The company has undergone changes in its board and management, with several members leaving and new appointments made, including the hiring of a new general manager[91]

证券代码：603976 证券简称：正川股份 重庆正川医药包装材料股份有限公司投资者关系活动记录表 编号：2022-001 | --- | --- | --- | --- | |-----------------------------|--------------------------------------------------------------|---------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | | 投资者关系活动 | □特定对象调研 □分析师会议 | | | | 类别 | □媒体采访 ...

2022 年第三季度报告 证券代码：603976 证券简称：正川股份 重庆正川医药包装材料股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 2022 年第三季度报告 | 套期保值业务外，持有交易性金融资 | | | | --- | --- | --- | | 产、衍生金融资产、交易性金融负债、 | | | | 衍生金融负债产生的公允价值变动 | | | | 损益，以及处置交易性金融资产、衍 | | | | 生金融资产、交易性金融负债、衍生 | | | | 金融负债和其他债权投资取得的投 | | | | 资收益 | | | | 单独进 ...